PMID- 24508508
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20220408
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Print)
IS  - 1550-4131 (Linking)
VI  - 19
IP  - 3
DP  - 2014 Mar 4
TI  - Rapamycin: one drug, many effects.
PG  - 373-9
LID - S1550-4131(14)00007-2 [pii]
LID - 10.1016/j.cmet.2014.01.001 [doi]
AB  - The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator 
      of cell growth and metabolism. Deregulation of the mTOR pathway has been 
      implicated in a number of human diseases such as cancer, diabetes, obesity, 
      neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of 
      mTOR, has been shown to be useful in the treatment of certain diseases. Here we 
      discuss its mechanism of action and highlight recent findings regarding the 
      effects and limitations of rapamycin monotherapy and the potential utility of 
      combination therapy with rapamycin.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Li, Jing
AU  - Li J
AD  - Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, 
      MA 02115, USA.
FAU - Kim, Sang Gyun
AU  - Kim SG
AD  - Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, 
      MA 02115, USA.
FAU - Blenis, John
AU  - Blenis J
AD  - Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, 
      MA 02115, USA. Electronic address: john_blenis@hms.harvard.edu.
LA  - eng
GR  - R01 CA046595/CA/NCI NIH HHS/United States
GR  - R01 GM051405/GM/NIGMS NIH HHS/United States
GR  - GM51405/GM/NIGMS NIH HHS/United States
GR  - R37 CA046595/CA/NCI NIH HHS/United States
GR  - CA46595/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20140206
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aging/drug effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Longevity/drug effects
MH  - Lung Diseases/drug therapy/metabolism/pathology
MH  - Metabolic Diseases/drug therapy/metabolism/pathology
MH  - Neoplasms/drug therapy/metabolism/pathology
MH  - Nervous System Diseases/drug therapy/metabolism/pathology
MH  - Signal Transduction/*drug effects
MH  - Sirolimus/*pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
PMC - PMC3972801
MID - NIHMS566634
EDAT- 2014/02/11 06:00
MHDA- 2014/11/05 06:00
PMCR- 2015/03/04
CRDT- 2014/02/11 06:00
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
PHST- 2015/03/04 00:00 [pmc-release]
AID - S1550-4131(14)00007-2 [pii]
AID - 10.1016/j.cmet.2014.01.001 [doi]
PST - ppublish
SO  - Cell Metab. 2014 Mar 4;19(3):373-9. doi: 10.1016/j.cmet.2014.01.001. Epub 2014 
      Feb 6.